SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Simona Francioso, Cristiana Almerighi, Paolo Forte, Franco Bandiera, Lorenzo Nosotti, Raffaella Lionetti, Gloria Taliani, Maria Rosaria Piras, Maria Laura Ponti, Giustino Parruti, Francesco Di Candilo, Silvia Gentile, Paola Piccolo, Angela Salso, Francesca Riccobelli, Sara Renzi, Maria Antonella Longo, Marzia Montalbano, Salvatore Zaru, Elisa Biliotti, Francesco Di Masi, Francesco Santopaolo, Mario Angelico, A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial, Digestive and Liver Disease, 2014, 46, 2, 164

    CrossRef

  2. 2
    Angelo Andriulli, Alessandra Nardi, Vito Di Marco, Antonio Massimo Ippolito, Caius Gavrila, Alessio Aghemo, Daniele Di Paolo, Giovanni Squadrito, Eleonora Grassi, Vincenza Calvaruso, Maria Rosa Valvano, Giuseppina Brancaccio, Antonio Craxi, Mario Angelico, An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C, Digestive and Liver Disease, 2014, 46, 9, 818

    CrossRef

  3. 3
    Johannes Vermehren, Alessio Aghemo, Karolin Falconer, Simone Susser, Giovanna Lunghi, Stefan Zeuzem, Massimo Colombo, Ola Weiland, Christoph Sarrazin, Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection, Journal of Hepatology, 2014, 60, 5, 913

    CrossRef

  4. 4
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  5. 5
    T.R. Lim, B.H. Tan, D.J. Mutimer, Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection, International Journal of Antimicrobial Agents, 2014, 43, 1, 17

    CrossRef

  6. 6
    Mitchell L. Shiffman, Hugo Cheinquer, Christoph P. Berg, Thomas Berg, Cláudio de Figueiredo-Mendes, Gregory J. Dore, Maria Lúcia Ferraz, Maria Cássia Mendes-Corrêa, Maria Patelli Lima, Edison R. Parise, Alma Minerva Perez Rios, Tania Reuter, Arun J. Sanyal, Stephen D. Shafran, Marc Hohmann, Fernando Tatsch, George Bakalos, Stefan Zeuzem, Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial, Hepatology International, 2014, 8, 4, 517

    CrossRef

  7. 7
    Brian L. Pearlman, Carole Ehleben, Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor, Hepatology, 2014, 59, 1
  8. 8
    Tomoyuki Takashima, Hirayuki Enomoto, Toshiaki Ninomiya, Soo Ryang Kim, Hiroaki Okushin, Masahiko Sugano, Susumu Imoto, Yoshihiko Yano, Teruji Ooka, Yasushi Seo, Hiroshi Kasugai, Akira Muramatsu, Hisato Jomura, Soji Shimomura, Michiko Shindo, Hideji Nakamura, Nobuhiro Aizawa, Yoshinori Iwata, Masaki Saito, Hiroyasu Imanishi, Hiroko Iijma, Shuhei Nishiguchi, Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment, Hepatology Research, 2014, 44, 6
  9. 9
    Alessandra Mangia, Tivadar Bányai, Giuseppe De Bartolomeo, Judit Gervain, François Habersetzer, Jean-Pierre Mulkay, Denis Ouzan, Giustino Parruti, Nicola Passariello, Andre-Jean Remy, Mario Rizzetto, Mitchell L. Shiffman, Alan D. Tice, Manuela Schmitz, Fernando Tatsch, Maribel Rodriguez-Torres, In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions, Liver International, 2014, 34, 7
  10. 10
    Hiroaki Okushin, Takeharu Yamamoto, Hiroshi Kishida, Kazuhiko Morii, Koichi Uesaka, Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon-beta followed by peginterferon plus ribavirin for genotype 1b high viral load, Hepatology Research, 2014, 44, 7
  11. 11
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  12. 12
    Daniela Ivanova Gerova, Bistra Tzaneva Galunska, Irina Ivanova Ivanova, Iskren Andreev Kotzev, Trifon Georgiev Tchervenkov, Svetlozar Petrov Balev, Dobrin Avramov Svinarov, Prevalence of vitamin D deficiency and insufficiency in Bulgarian patients with chronic Hepatitis C viral infection, Scandinavian Journal of Clinical & Laboratory Investigation, 2014, 74, 8, 665

    CrossRef

  13. 13
    Ai Nakagawa, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Chisa Kondo, Norio Itokawa, Taeang Arai, Satomi Hashimoto, Yoko Matsushita, Takeshi Fukuda, Katsuhisa Nakatsuka, Katsuhiko Iwakiri, Chiaki Kawamoto, Yoshio Aizawa, Choitsu Sakamoto, Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy, European Journal of Gastroenterology & Hepatology, 2014, 26, 12, 1329

    CrossRef

  14. 14
    Hoang Hai, Akihiro Tamori, Masaru Enomoto, Hiroyasu Morikawa, Sawako Uchida-Kobayashi, Hideki Fujii, Atsushi Hagihara, Etsushi Kawamura, Le Thi Thanh Thuy, Yasuhito Tanaka, Norifumi Kawada, Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin, Journal of Gastroenterology and Hepatology, 2014, 29, 1
  15. 15
    Eric J Lawitz, Fernando E Membreno, Response-guided therapy in patients with genotype 1 hepatitis C virus: Current status and future prospects, Journal of Gastroenterology and Hepatology, 2014, 29, 8
  16. 16
    Francesco Azzaroli, Marco Montagnani, Alberto Porro, Domenico Fiorillo, Giuseppe Mazzella, The future of dual therapy for hepatitis C virus, Future Virology, 2014, 9, 10, 905

    CrossRef

  17. 17
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Sadaharu Iio, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara, Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1, Journal of Gastroenterology, 2014, 49, 4, 737

    CrossRef

  18. You have free access to this content18
    Tsugiko Oze, Naoki Hiramatsu, Eiji Mita, Norio Akuta, Naoya Sakamoto, Hiroaki Nagano, Yoshito Itoh, Shuichi Kaneko, Namiki Izumi, Hideyuki Nomura, Norio Hayashi, Tetsuo Takehara, A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan, Hepatology Research, 2013, 43, 1
  19. 19
    Haruki Komatsu, Ayano Inui, Tomoyuki Tsunoda, Tsuyoshi Sogo, Tomoo Fujisawa, Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection, Hepatology Research, 2013, 43, 4
  20. 20
    Kung-Hung Lin, Hsien-Chung Yu, Ping-I Hsu, Wei-Lun Tsai, Wen-Chi Chen, Chun-Ku Lin, Hoi-Hung Chan, Fong-Wei Tsay, Kwok-Hung Lai, Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy, Hepatitis Monthly, 2013, 13, 10

    CrossRef

  21. 21
    Parveen Kaur, Justin Jang Hann Chu, Chikungunya virus: an update on antiviral development and challenges, Drug Discovery Today, 2013, 18, 19-20, 969

    CrossRef

  22. 22
    Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Norio Itokawa, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Tamaki Kobayashi, Hidenori Kanazawa, Choitsu Sakamoto, Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  23. 23
    Daria J. Hazuda, Margaret Burroughs, Anita Y.M. Howe, Janice Wahl, Srikanth Venkatraman, Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection, Annals of the New York Academy of Sciences, 2013, 1291, 1
  24. 24
    A. Andriulli, A. Iacobellis, M. R. Valvano, F. Spirito, A. Ippolito, F. Bossa, F. Terracciano, R. Fontana, G. Niro, Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin, Digestive Diseases and Sciences, 2013, 58, 5, 1371

    CrossRef

  25. 25
    Savino Bruno, Alessandra Mangia, Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era, Digestive and Liver Disease, 2013, 45, 5, 356

    CrossRef

  26. 26
    Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba, Sustained and rapid virological responses in hepatitis C clinical trials, Clinical Investigation, 2013, 3, 11, 1083

    CrossRef

  27. 27
    Leah C. Burns, Lucinda Orsini, Gilbert L’Italien, Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use, Value in Health, 2013, 16, 6, S16

    CrossRef

  28. 28
    Sumiko Nagoshi, Yohei Koshima, Ikuo Nakamura, Junji Funyu, Chuichi Sekine, Youji Harada, Ko Nishikawa, Takeshi Yoshida, Atsushi Matsui, Naoki Sotome, Kenichi Toshima, So Takegoshi, Masao Shiomi, Masahiko Tanaka, Akira Saito, Kenji Fujiwara, Satoshi Mochida, A Multicenter Study to Clarify the Optimal HCV-RNA Negative Period during Combined Therapy with Pegylated Interferon Plus Ribavirin in Patients with Chronic Hepatitis Caused by HCV Genotype 2, Internal Medicine, 2012, 51, 1, 9

    CrossRef

  29. 29
    Ziad F. Gellad, Andrew J. Muir, John G. McHutchison, William Sievert, Ala I. Sharara, Kimberly A. Brown, Robert Flisiak, Ira M. Jacobson, David Kershenobich, Michael P. Manns, Kevin A. Schulman, Shelby D. Reed, Cost-Effectiveness of Truncated Therapy for Hepatitis C Based on Rapid Virologic Response, Value in Health, 2012, 15, 6, 876

    CrossRef

  30. You have free access to this content30
    E. W. Hwang, I.-C. Thomas, R. Cheung, L. I. Backus, Implications of rapid virological response in hepatitis C therapy in the US veteran population, Alimentary Pharmacology & Therapeutics, 2012, 35, 1
  31. 31
    Chung-Feng Huang, Jee-Fu Huang, Jeng-Fu Yang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Suh-Hang Hank Juo, Ku-Chung Chen, Wan-Long Chuang, Hsing-Tao Kuo, Chia-Yen Dai, Ming-Lung Yu, Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin, Journal of Hepatology, 2012, 56, 1, 34

    CrossRef

  32. 32
    Nadia El Ansary, Hisham Samy Abd El Fattah, Manal Ghozlan, Laila El Shabrawy, Long-term follow-up of responder and super-responder chronic hepatitis C Egyptian patients treated with interferon α-2a plus ribavirin, Egyptian Liver Journal, 2012, 2, 4, 103

    CrossRef

  33. 33
    P. Ferenci, Optimal treatment duration for patients with HCV genotype 1 infection, Journal of Viral Hepatitis, 2012, 19,
  34. 34
    S. Zeuzem, M. Rodríguez-Torres, K. Rajender Reddy, P. Marcellin, M. Diago, A. Craxi, P. Pockros, M. Rizzetto, D. Bernstein, M. L. Shiffman, A. Lin, F. Tatsch, S. Hadziyannis, Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin, Journal of Viral Hepatitis, 2012, 19, 11
  35. 35
    A. Craxi, S. Koutsounas, P. Ogurtsov, L. Chemello, M. Maticic, J. Torras, M. Diago, M. T. Tartaglione, T. Witthoeft, X. Yu, R. Faruqi, E. Chaudhri, L. D. Pedicone, E. Zuckerman, Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response, Journal of Viral Hepatitis, 2012, 19, 2
  36. You have free access to this content36
    S. S. Lee, M. Sherman, A. Ramji, S. Greenbloom, M. Elkashab, H. Pluta, N. Hilzenrat, R. Balshaw, C. Usaty, R. P. Myers, Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3, Alimentary Pharmacology & Therapeutics, 2012, 35, 1
  37. 37
    Dae Won Jun, Won Young Tak, Si Hyun Bae, Youn Jae Lee, Recent trends in the treatment of chronic hepatitis C, The Korean Journal of Hepatology, 2012, 18, 1, 22

    CrossRef

  38. 38
    Tsugiko Oze, Naoki Hiramatsu, Changho Song, Takayuki Yakushijin, Sadaharu Iio, Yoshinobu Doi, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Eijiro Hayashi, Michio Kato, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara, Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin, Journal of Gastroenterology, 2012, 47, 3, 334

    CrossRef

  39. 39
    Patrick Marcellin, Nancy Reau, Peter Ferenci, Stephanos Hadziyannis, Diethelm Messinger, Fernando Tatsch, Donald Jensen, Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin, Journal of Hepatology, 2012, 56, 6, 1276

    CrossRef

  40. 40
    Peter Ferenci, Response guided therapy in patients with chronic hepatitis C – Yesterday, today and tomorrow, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 463

    CrossRef

  41. 41
    K. Rajender Reddy, Frederick Lin, Fabien Zoulim, Response-guided and -unguided treatment of chronic hepatitis C, Liver International, 2012, 32,
  42. 42
    Sarah Maylin, Cédric Laouénan, Michelle Martinot-Peignoux, Xavière Panhard, Martine Lapalus, Marie Hélène Nicolas-Chanoine, Pierre Bedossa, Tarik Asselah, Patrick Marcellin, Role of hepatic HCV–RNA level on the severity of chronic hepatitis C and response to antiviral therapy, Journal of Clinical Virology, 2012, 53, 1, 43

    CrossRef

  43. 43
    I. M. Jacobson, F. Poordad, R. S. Brown Jr, P. Y. Kwo, K. R. Reddy, E. Schiff, Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations, Journal of Viral Hepatitis, 2012, 19, 4
  44. 44
    Takeshi Nishimura, Kanji Yamaguchi, Hiroaki Hashimoto, Toshihisa Niimi, Chihiro Yokomizo, Hideki Fujii, Masahito Minami, Masafumi Sakamoto, Naoki Ohnish, Yasuyuki Nagao, Mika Okita, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh, Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy, Hepatology Research, 2012, 42, 10
  45. 45
    Dae Won Jun, Treatment of chronic hepatitis C, Journal of the Korean Medical Association, 2012, 55, 11, 1113

    CrossRef

  46. 46
    Mario Masarone, Marcello Persico, Antiviral therapy: why does it fail in HCV-related chronic hepatitis?, Expert Review of Anti-infective Therapy, 2011, 9, 5, 535

    CrossRef

  47. 47
    Paul Y. Kwo, Rong Zhao, Boceprevir: A User’s Guide, Clinics in Liver Disease, 2011, 15, 3, 537

    CrossRef

  48. 48
    Stevan A. Gonzalez, Consensus Interferon: Tailored Therapy and the Impact of Adherence, Digestive Diseases and Sciences, 2011, 56, 3, 631

    CrossRef

  49. 49
    I. Dzyublyk, T. Yegorova, L. Moroz, O. Popovych, I. Zaytsev, V. Miroshnichenko, A. Kromminga, M. M. Wilkes, E. J. van Hoogdalem, J. E. Humphries, Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial, Journal of Viral Hepatitis, 2011, 18, 4
  50. 50
    McKenzie C. Ferguson, Current Therapies for Chronic Hepatitis C, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 1
  51. 51
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2011, 55, 2, 245

    CrossRef

  52. 52
    M. Parikh, A. Singh, G. Sood, Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin, Journal of Viral Hepatitis, 2011, 18, 4
  53. 53
    Mitchell L. Shiffman, HCV Response-Guided Therapy: Should Treatment Length Be Shortened or Extended?, Current Hepatitis Reports, 2011, 10, 1, 4

    CrossRef

  54. 54
    Olav Dalgard, Zbigniew Konopski, Franziskus Bosse, Berit Nordstrand, Per Sandvei, Lars Karlsen, Jon Florholmen, Astrid Rojahn, Rune Almaas, Steinar Skrede, Arne Eskesen, Bjørn Myrvang, Hepatitt C - utredning og behandling, Tidsskrift for Den norske legeforening, 2011, 131, 1, 2

    CrossRef

  55. 55
    Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Takahiro Arakawa, Masashi Fujimori, Takuro Niinomi, Naoto Ando, Satoshi Yasuda, Keisuke Sakai, Jun Kimura, High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b, Journal of Gastroenterology, 2011, 46, 4, 501

    CrossRef

  56. 56
    Thomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, Hermann Laferl, Andreas Maieron, Rudolf Stauber, Christian Datz, Emina Dulic-Lakovic, Petra Steindl-Munda, Harald Hofer, Peter Ferenci, Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin, Hepatology, 2011, 54, 5
  57. 57
    J. Wiegand, K. Neumann, S. Bohm, V. Weich, G. Teuber, H. Klinker, B. Moller, J. Rasenack, H. Hinrichsen, T. Gerlach, U. Spengler, P. Buggisch, C. Sarrazin, T. Berg, Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection, Clinical Infectious Diseases, 2011, 53, 11, 1111

    CrossRef

  58. 58
    Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, Gerlinde Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O. Boecher, Ewert Schulte–Frohlinde, Renate Prinzing, Eva Herrmann, Stefan Zeuzem, Thomas Berg, Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks, Gastroenterology, 2011, 141, 5, 1656

    CrossRef

  59. 59
    Alessandra Mangia, Alexander J. Thompson, Rosanna Santoro, Valeria Piazzolla, Massimiliano Copetti, Nicola Minerva, Daniela Petruzzellis, Leonardo Mottola, Donato Bacca, John G. McHutchison, Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring, Hepatology, 2011, 54, 3
  60. 60
    A. Martinez-Camacho, V.I. Khaoustov, E. Adam, D.E. Lewis, S. Tavakoli-Tabasi, B. Yoffe, Lymphocytosis as a predictor of poor response to treatment of hepatitis C, Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 1, 34

    CrossRef

  61. 61
    Johannes Vermehren, Ming-Lung Yu, Alexander Monto, Joseph D. Yao, Christopher Anderson, Rasa Bertuzis, George Schneider, Christoph Sarrazin, Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C, Journal of Clinical Virology, 2011, 52, 2, 133

    CrossRef

  62. 62
    Seyed Moayed Alavian, Seyed Vahid Tabatabaei, Bita Behnava, Nastaran Mahboobi, Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis, Hepatitis Monthly, 2011, 11, 8, 612

    CrossRef

  63. 63
    Michael W. Fried, Stephanos J. Hadziyannis, Mitchell L. Shiffman, Diethelm Messinger, Stefan Zeuzem, Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection, Journal of Hepatology, 2011, 55, 1, 69

    CrossRef

  64. 64
    T.-M. Chen, P.-T. Huang, C.-F. Wen, J.-N. Tung, K.-C. Chow, Y.-P. Chen, Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy, Journal of Viral Hepatitis, 2011, 18, 2
  65. 65
    Vincent Di Martino, Carine Richou, Jean-Paul Cervoni, Jose M. Sanchez-Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot, Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future, Hepatology, 2011, 54, 3
  66. 66
    Mary Olson, Ira M. Jacobson, Role of the nurse practitioner in the management of patients with chronic hepatitis C, Journal of the American Academy of Nurse Practitioners, 2011, 23, 8
  67. 67
    Renato Bonardi, Marco Tabone, Aldo Manca, Rinaldo Pellicano, Alessia Ciancio, Mario Rizzetto, Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin, Biomedicine & Pharmacotherapy, 2011, 65, 4, 303

    CrossRef

  68. 68
    Rebecca Townsend, Phil McEwan, Ray Kim, Yong Yuan, Structural Frameworks and Key Model Parameters in Cost-Effectiveness Analyses for Current and Future Treatments of Chronic Hepatitis C, Value in Health, 2011, 14, 8, 1068

    CrossRef

  69. 69
    Ira M. Jacobson, John G. McHutchison, Geoffrey Dusheiko, Adrian M. Di Bisceglie, K. Rajender Reddy, Natalie H. Bzowej, Patrick Marcellin, Andrew J. Muir, Peter Ferenci, Robert Flisiak, Jacob George, Mario Rizzetto, Daniel Shouval, Ricard Sola, Ruben A. Terg, Eric M. Yoshida, Nathalie Adda, Leif Bengtsson, Abdul J. Sankoh, Tara L. Kieffer, Shelley George, Robert S. Kauffman, Stefan Zeuzem, Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection, New England Journal of Medicine, 2011, 364, 25, 2405

    CrossRef

  70. 70
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Kiyoshi Mochizuki, Kazuho Imanaka, Akira Yamada, Masahide Oshita, Akira Kaneko, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Toshihiko Nagase, Yoshiaki Inui, Taizo Hijioka, Shinji Tamura, Harumasa Yoshihara, Eijiro Hayashi, Yasuharu Imai, Michio Kato, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Tetsuo Takehara, Norio Hayashi, The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan, Journal of Gastroenterology, 2011, 46, 7, 944

    CrossRef

  71. 71
    Y. Q. Zhou, X. H. Wang, G. H. Hong, Y. Zhu, X. Q. Zhang, Y. J. Hu, Q. Mao, Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a, Journal of Viral Hepatitis, 2011, 18, 8
  72. 72
    Pierre Deltenre, Marion Corouge, Valérie Canva, Hélène Castel, Faustine Wartel, Sébastien Dharancy, Alexandre Louvet, Mouna Lazrek, Christophe Moreno, Jean Henrion, Philippe Mathurin, Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin, Journal of Hepatology, 2011, 55, 5, 989

    CrossRef

  73. 73
    Tetsuo TAKEHARA, Antiviral Therapy for Chronic Hepatitis C: Current Status and Perspectives, YAKUGAKU ZASSHI, 2010, 130, 2, 143

    CrossRef

  74. 74
    Ching-Sheng Hsu, Chen-Hua Liu, Chun-Jen Liu, Shih-Jer Hsu, Chi-Ling Chen, Juey-Jen Hwang, Ming-Yang Lai, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Association of metabolic profiles with hepatic fibrosis in chronic hepatitis C patients with genotype 1 or 2 infection, Journal of Gastroenterology and Hepatology, 2010, 25, 5
  75. 75
    Christoph Sarrazin, Mitchell L. Shiffman, Stephanos J. Hadziyannis, Amy Lin, Giuseppe Colucci, Hiroshi Ishida, Stefan Zeuzem, Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy, Journal of Hepatology, 2010, 52, 6, 832

    CrossRef

  76. 76
    M. Rodriguez-Torres, F. Torriani, J. Rockstroh, J. Depamphilis, G. Carosi, D.T. Dieterich, Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin, HIV Clinical Trials, 2010, 11, 1, 1

    CrossRef

  77. 77
    M. Rodriguez-Torres, F. Torriani, J. Rockstroh, J. Depamphilis, G. Carosi, D.T. Dieterich, Degree of Viral Decline Early in Treatment Predicts Sustained Virological Response in HCV-HIV Coinfected Patients Treated with Peginterferon Alfa-2a and Ribavirin, HIV Clinical Trials, 2010, 11, 1, 1

    CrossRef

  78. 78
    Chung-Feng Huang, Jeng-Fu Yang, Jee-Fu Huang, Chia-Yen Dai, Chang-Fu Chiu, Nai-Jen Hou, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang, Ming-Lung Yu, Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response, Journal of Gastroenterology and Hepatology, 2010, 25, 4
  79. 79
    Savino Bruno, Mitchell L. Shiffman, Stuart K. Roberts, Edward J. Gane, Diethelm Messinger, Stephanos J. Hadziyannis, Patrick Marcellin, Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis, Hepatology, 2010, 51, 2
  80. 80
    Chun-Hao Chen, Ming-Lung Yu, Evolution of Interferon-Based Therapy for Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1

    CrossRef

  81. 81
    M. Rodriguez-Torres, M. S. Sulkowski, R. T. Chung, F. M. Hamzeh, D. M. Jensen, Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population, Journal of Viral Hepatitis, 2010, 17, 2
  82. 82
    Tsung-Ming Chen, Pi-Teh Huang, Ching-Heng Lin, Ming-Hung Tsai, Lien-Fu Lin, Chung-Cheng Liu, Ka-Sic Ho, Jai-Nien Tung, Feasibility of individualized treatment for hepatitis C patients in the real world, Journal of Gastroenterology and Hepatology, 2010, 25, 1
  83. 83
    Marc Deschênes, Vincent G. Bain, Samuel S. Lee, Morris Sherman, Curtis L. Cooper, Eric M. Yoshida, Paul J. Marotta, Mel Krajden, Christopher Usaty, Robert Balshaw, Kevork M. Peltekian, Identifying HCV genotype 1 patients at risk of relapse, European Journal of Gastroenterology & Hepatology, 2010, 22, 5, 546

    CrossRef

  84. 84
    Narci C Teoh, Geoffrey C Farrell, Henry L-Y Chan, Individualisation of antiviral therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2010, 25, 7
  85. 85
    Alessandra Mangia, Franco Bandiera, Giuseppe Montalto, Leonardo Mottola, Valeria Piazzolla, Nicola Minerva, Adriano Pellicelli, Giovanni L. Ricci, Marina Cela, Vito Carretta, Gaetano Scotto, Donato Bacca, Brigida Annicchiarico, Mario Romano, Maurizio Russello, Giorgio Barbarini, Ernesto Agostinacchio, Angelo Andriulli, Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3, Journal of Hepatology, 2010, 53, 6, 1000

    CrossRef

  86. 86
    Wendy S.C. Cheng, Stuart K. Roberts, Geoffrey McCaughan, William Sievert, Martin Weltman, Darrell Crawford, William Rawlinson, Philippa S. Marks, James Thommes, Bishoy Rizkalla, Motoko Yoshihara, Gregory J Dore, Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing, Journal of Hepatology, 2010, 53, 4, 616

    CrossRef

  87. 87
    François Bailly, Si Nafa Si Ahmed, Pierre Pradat, Christian Trepo, Management of nonresponsive hepatitis C, Expert Review of Anti-infective Therapy, 2010, 8, 4, 379

    CrossRef

  88. 88
    Harald Farnik, Christian M. Lange, Christoph Sarrazin, Bernd Kronenberger, Stefan Zeuzem, Eva Herrmann, Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection, Clinical Gastroenterology and Hepatology, 2010, 8, 10, 884

    CrossRef

  89. 89
    Conrado M. Fernández Rodríguez, Sonia Alonso López, Optimización del tratamiento de la hepatitis crónica por virus C, Gastroenterología y Hepatología, 2010, 33, 2, 119

    CrossRef

  90. 90
    In Hee Kim, Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response, The Korean Journal of Hepatology, 2010, 16, 2, 201

    CrossRef

  91. 91
    Peter Ferenci, Hermann Laferl, Thomas–Matthias Scherzer, Andreas Maieron, Harald Hofer, Rudolf Stauber, Michael Gschwantler, Harald Brunner, Christoph Wenisch, Martin Bischof, Michael Strasser, Christian Datz, Wolfgang Vogel, Karin Löschenberger, Petra Steindl–Munda, Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response, Gastroenterology, 2010, 138, 2, 503

    CrossRef

  92. 92
    Graham R. Foster, Pegylated Interferons for the Treatment of Chronic Hepatitis C, Drugs, 2010, 70, 2, 147

    CrossRef

  93. 93
    Stefan Zeuzem, Fred Poordad, Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response, Current Medical Research and Opinion, 2010, 26, 7, 1733

    CrossRef

  94. 94
    Mazen Noureddin, Marc G. Ghany, Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis C, Gastroenterology Clinics of North America, 2010, 39, 3, 649

    CrossRef

  95. 95
    Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting, Digestive and Liver Disease, 2010, 42, 2, 81

    CrossRef

  96. 96
    Maria Buti, Yoav Lurie, Natalia G. Zakharova, Natalia P. Blokhina, Andrzej Horban, Gerlinde Teuber, Christoph Sarrazin, Ligita Balciuniene, Saya V. Feinman, Rab Faruqi, Lisa D. Pedicone, Rafael Esteban, Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response, Hepatology, 2010, 52, 4
  97. 97
    Michiyasu Yagura, Akihisa Tanaka, Hiroshi Kamitsukasa, Hiroki Otsuka, Sotaro Kanno, Toshihisa Aoyama, Re-evaluation of the Serum Alanine Aminotransferase Upper Normal Limit in Chronic Hepatitis C Patients, Internal Medicine, 2010, 49, 6, 525

    CrossRef

  98. 98
    Catherine François, Véronique Descamps, Etienne Brochot, Isabelle Bernard, Valérie Canva, Philippe Mathurin, Sandrine Castelain, Gilles Duverlie, Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy, Journal of Medical Virology, 2010, 82, 10
  99. You have free access to this content99
    F. F. POORDAD, Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2010, 31, 12
  100. 100
    Christophe Moreno, Pierre Deltenre, Jean-Michel Pawlotsky, Jean Henrion, Michael Adler, Philippe Mathurin, Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: A meta-analysis, Journal of Hepatology, 2010, 52, 1, 25

    CrossRef

  101. 101
    Paul Kwo, Viral Kinetics and Duration of Hepatitis C Therapy, Current Hepatitis Reports, 2010, 9, 3, 140

    CrossRef

  102. 102
    Kenneth E. Sherman, Halim Muslu, GI/Liver Secrets, 2010,

    CrossRef

  103. 103
    JULES L. DIENSTAG, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  104. 104
    Jacqueline G. O’Leary, Gary L. Davis, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  105. 105
    Tatsuya Ide, Teruko Hino, Kei Ogata, Ichiro Miyajima, Reiichiro Kuwahara, Koichiro Kuhara, Michio Sata, A Randomized Study of Extended Treatment With Peginterferon α-2b Plus Ribavirin Based on Time to HCV RNA Negative–Status in Patients With Genotype 1b Chronic Hepatitis C, The American Journal of Gastroenterology, 2009, 104, 1, 70

    CrossRef

  106. You have free access to this content106
    M. NAGAKI, M. SHIMIZU, J. I. SUGIHARA, E. TOMITA, C. SANO, T. NAIKI, K. KIMURA, K. AMANO, T. SAKAI, M. NINOMIYA, T. KOJIMA, N. KATSUMURA, M. FUJIMOTO, H. MORIWAKI, Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders, Alimentary Pharmacology & Therapeutics, 2009, 30, 4
  107. 107
    Leonardo Baiocchi, Ilaria Lenci, Marco Carbone, Mario Angelico, Comment on the PROVE1 and PROVE2 clinical trials: “I was taking a picture of rapid virological response with telaprevir, but the background is unfocused!”, Hepatology, 2009, 50, 5
  108. 108
    Okba Haj-Ali Saflo, Jesús Miguel Hernández Guijo, Coste-eficacia del tratamiento de la hepatitis C crónica en España, Gastroenterología y Hepatología, 2009, 32, 7, 472

    CrossRef

  109. 109
    Hideyuki Nomura, Yugo Miyagi, Hironori Tanimoto, Masashi Higashi, Hiromi Ishibashi, Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices, Journal of Gastroenterology, 2009, 44, 4, 338

    CrossRef

  110. 110
    Wyel Hakim, Shehzad Sheikh, Irteza Inayat, Cary Caldwell, Douglas Smith, Marc Lorber, Amy Friedman, Dhanpat Jain, Margaret Bia, Richard Formica, Wajahat Mehal, HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin, Journal of Clinical Gastroenterology, 2009, 43, 5, 477

    CrossRef

  111. 111
    P. Gerner, S. Wirth, Hepatitis B und C im Kindesalter, Monatsschrift Kinderheilkunde, 2009, 157, 2, 177

    CrossRef

  112. 112
    David R. Nelson, Gary L. Davis, Ira Jacobson, Gregory T. Everson, Michael W. Fried, Stephen A. Harrison, Tarek Hassanein, Donald M. Jensen, Karen L. Lindsay, Norah Terrault, Nizar Zein, Hepatitis C Virus: A Critical Appraisal of Approaches to Therapy, Clinical Gastroenterology and Hepatology, 2009, 7, 4, 397

    CrossRef

  113. 113
    Thomas Berg, Viola Weich, Gerlinde Teuber, Hartwig Klinker, Bernd Möller, Jens Rasenack, Holger Hinrichsen, Tilman Gerlach, Ulrich Spengler, Peter Buggisch, Heike Balk, Myrga Zankel, Konrad Neumann, Christoph Sarrazin, Stefan Zeuzem, Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients, Hepatology, 2009, 50, 2
  114. 114
    Alessandro Grasso, Federica Malfatti, Pasqualina De Leo, Hugo Martines, Paolo Fabris, Federica Toscanini, Marco Anselmo, Giorgio Menardo, Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin, Journal of Hepatology, 2009, 51, 6, 984

    CrossRef

  115. 115
    D. T. Dieterich, M. Rizzetto, M. P. Manns, Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 12
  116. 116
    Philippe Halfon, Denis Ouzan, Monitoring virologique optimal de l’hépatite C en 2009 : la durée du traitement dépend de la rapidité de la réponse virologique et de la durée de négativation, La Presse Médicale, 2009, 38, 7-8, 1037

    CrossRef

  117. 117
    P. Cacoub, P. Halfon, Monitoring virologique optimisé du traitement de l’hépatite C en 2009, La Revue de Médecine Interne, 2009, 30, 10, 838

    CrossRef

  118. 118
    Nipaporn Pichetshote, Erik Groessl, Helen Yee, Samuel B. Ho, Optimizing the Dose and Duration of Therapy for ChronicHepatitis C, Gut and Liver, 2009, 3, 1, 1

    CrossRef

  119. 119
    Catherine François, Sandrine Castelain, Gilles Duverlie, Dominique Capron, Eric Nguyen-Khac, Optimizing the treatment of chronic viral hepatitis C, Expert Review of Gastroenterology & Hepatology, 2009, 3, 6, 607

    CrossRef

  120. 120
    Thierry Poynard, Massimo Colombo, Jordi Bruix, Eugene Schiff, Ruben Terg, Steven Flamm, Ricardo Moreno-Otero, Flair Carrilho, Warren Schmidt, Thomas Berg, Thomas McGarrity, E. Jenny Heathcote, Fernando Gonçales, Moises Diago, Antonio Craxi, Marcelo Silva, Pierre Bedossa, Pabak Mukhopadhyay, Louis Griffel, Margaret Burroughs, Clifford Brass, Janice Albrecht, Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy, Gastroenterology, 2009, 136, 5, 1618

    CrossRef

  121. 121
    M. Ghabril, R. C. Dickson, M. Krishna, R. Lloyd, J. Aranda-Michel, A. Keaveny, R. Satyanarayana, H. Bonatti, Persistence of Hepatitis C RNA in Liver Allografts Is Associated with Histologic Progression Independent of Serologic Viral Clearance, Journal of Transplantation, 2009, 2009, 1

    CrossRef

  122. 122
    Keiji Tsuji, Yoshiiku Kawakami, Shiomi Aimitsu, Hiroshi Kohno, Yasuyuki Aisaka, Shigeru Kimura, Shinji Nagata, Hiroaki Ohgoshi, Mikiya Kitamoto, Tohru Hidaka, Hiroiku Kawakami, Toshio Nakanishi, Kazuaki Chayama, Predicting the response to 48-week combination therapy with peginterferon α-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients, Hepatology Research, 2009, 39, 6
  123. 123
    Noritomo Shimada, Kai Yoshizawa, Makiko Ika, Akira Dobashi, Naoto Nomura, Gotaro Toda, Akihito Tsubota, Hiroshi Abe, Yoshio Aizawa, Response-guided therapy in Japanese chronic hepatitis C patients infected with genotype 1b and high viral load, Kanzo, 2009, 50, 12, 687

    CrossRef

  124. 124
    N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara, N. Hayashi, Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin, Journal of Viral Hepatitis, 2009, 16, 8
  125. 125
    Hiroki Ikeda, Michihiro Suzuki, Chiaki Okuse, Norie Yamada, Masaru Okamoto, Minoru Kobayashi, Yoshihiko Nagase, Hideaki Takahashi, Koutarou Matsunaga, Nobuyuki Matsumoto, Fumio Itoh, Hiroshi Yotsuyanagi, Yu Koitabashi, Kiyomi Yasuda, Shiro Iino, Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response, Hepatology Research, 2009, 39, 8
  126. 126
    Heiner Wedemeyer, Elisabeth Schuller, Verena Schlaphoff, Rudolf E. Stauber, Johannes Wiegand, Ingolf Schiefke, Christa Firbas, Bernd Jilma, Mark Thursz, Stefan Zeuzem, Wolf P. Hofmann, Holger Hinrichsen, Erich Tauber, Michael P. Manns, Christoph S. Klade, Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C, Vaccine, 2009, 27, 37, 5142

    CrossRef

  127. 127
    Ming-Lung Yu, Wan-Long Chuang, Treatment of chronic hepatitis C in Asia: When East meets West, Journal of Gastroenterology and Hepatology, 2009, 24, 3
  128. 128
    Bulent Degertekin, Anna SF Lok, Update on viral hepatitis: 2008, Current Opinion in Gastroenterology, 2009, 25, 3, 180

    CrossRef

  129. 129
    Fred Poordad, Nancy Reau, Viral-guided hepatitis C therapy, Current Hepatitis Reports, 2009, 8, 2, 66

    CrossRef

  130. 130
    H. PATEL, E. J. HEATHCOTE, When to treat and the benefits of treating hepatitis C in patients with haemophilia, Haemophilia, 2009, 15, 1
  131. 131
    Stefan Zeuzem, Interferon-based therapy for chronic hepatitis C: current and future perspectives, Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5, 11, 610

    CrossRef

  132. 132
    Eliana Z. Agudelo, Norah A. Terrault, Optimizing therapy in treatment-naïve genotype 1 patients, Current Hepatitis Reports, 2008, 7, 2, 64

    CrossRef

  133. 133
    P. Ferenci, Peginterferon and ribavirin in HCV: Improvement of sustained viral response, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1109

    CrossRef

  134. 134
    Susan J Keam, Risto S Cvetković, Peginterferon-α-2a (40 kD) Plus Ribavirin, Drugs, 2008, 68, 9, 1273

    CrossRef

  135. 135
    Chen-Hua Liu, Chun-Jen Liu, Chih-Lin Lin, Cheng-Chao Liang, Shih-Jer Hsu, Sheng-Shun Yang, Ching-Sheng Hsu, Tai-Chung Tseng, Chia-Chi Wang, Ming-Yang Lai, Jun-Herng Chen, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao, Pegylated Interferon-α-2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial, Clinical Infectious Diseases, 2008, 47, 10, 1260

    CrossRef

  136. 136
    Liam J. Fanning, Practical Consequences of Hepatitis C Virus Quasispecies for Target-Specific Antivirals, The Journal of Infectious Diseases, 2008, 198, 6, 797

    CrossRef

  137. 137
    Ming-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, Chang-Fu Chiu, Yi-Hsin C. Yang, Nai-Jen Hou, Li-Po Lee, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang, Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial, Hepatology, 2008, 47, 6
  138. 138
    Ming-Lung Yu, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: The role of weight-based ribavirin exposure, Hepatology, 2008, 48, 3
  139. 139
    Alessandra Mangia, Angelo Andriulli, Reply:, Hepatology, 2008, 48, 3
  140. 140
    Annika Kau, Johannes Vermehren, Christoph Sarrazin, Treatment predictors of a sustained virologic response in hepatitis B and C, Journal of Hepatology, 2008, 49, 4, 634

    CrossRef

  141. 141
    J. Morello, S. Rodriguez-Novoa, I. Jimenez-Nacher, V. Soriano, Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C, Journal of Antimicrobial Chemotherapy, 2008, 62, 6, 1174

    CrossRef

  142. 142
    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili, Ran Tur-Kaspa, Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients, The Cochrane Library,
  143. 143
    Rebekah G. Gross, Ira M. Jacobson, Genotype 1: Standard Treatment,
  144. 144
    W. Ray Kim, John J. Poterucha, Hepatitis B and C,
  145. 145
    Jama M. Darling, Stanley M. Lemon, Michael W. Fried, Hepatitis C,
  146. 146
    Sanaa M. Kamal, Hepatitis C Genotype 4 Therapy: Progress and Challenges,
  147. 147
    Johannes Wiegand, Thomas Berg, Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients,
  148. 148
    Ronald L Koretz, Maria Pleguezuelo, Vasiliki Arvaniti, Pilar Barrera Baena, Ruben Ciria, Kurinchi Selvan Gurusamy, Brian R Davidson, Andrew K Burroughs, Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C, The Cochrane Library,